Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: Longitudinal associations

International Journal of Obesity

Volumn 32, Issue 5, 2008, Pages 740-748

  Wildman, R P ^a   Mancuso, P ^b   Wang, C ^a   Kim, M ^a   Scherer, P E ^c   Sowers, M R ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Adipocytokines; Adiponectin; Cardiovascular risk factors; Longitudinal; Women

Indexed keywords

ADIPONECTIN; GHRELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; RESISTIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADIPOKINES; ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; BODY WEIGHTS AND MEASURES; CARDIOVASCULAR DISEASES; FEMALE; GHRELIN; HUMANS; LONGITUDINAL STUDIES; MENOPAUSE; MIDDLE AGED; RESISTIN; RISK FACTORS;

EID: 43449091901     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803782     Document Type: Article

References (62)

1. Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162: 2557-2562.
2. Dey DK, Rothenberg E, Sundh V, Bosaeus I, Steen B. Waist circumference, body mass index, and risk for stroke in older people: a 15 year longitudinal population study of 70-year-olds. J Am Geriatr Soc 2002; 50: 1510-1518.
3. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-1872.
4. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002; 156: 832-841.
5. Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-418.
6. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
7. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005; 46: 379-380.
8. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056.
9. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
10. Nakamura K, Ueno T, Yamamoto H, Iguro Y, Yamada K, Sakata R. Relationship between cerebral injury and inflammatory responses in patients undergoing cardiac surgery with cardiopulmonary bypass. Cytokine 2005; 29: 95-104.
11. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.
12. Webber J. Energy balance in obesity. Proc Nutr Soc 2003; 62: 539-543.
13. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (dioseost abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
14. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-11256.
15. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RVet al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-{gamma} action in humans. Diabetes 2001; 50: 2199-2202.
16. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
17. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276: 905-908.
18. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
19. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240-244.
20. Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007; 92: 895-901.
21. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 2001; 32: 1104-1111.
22. Otsuki M, Kasayama S, Morita S, Asanuma N, Saito H, Mukai M et al. Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause 2007; 14: 404-407.
23. Mesch VR, Boero LE, Siseles NO, Royer M, Prada M, Sayegh F et al. Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. Climacteric 2006; 9: 40-48.
24. Warnick GR, Albers JJ. A comprehensive evaluation of heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978; 19: 65.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
26. Boulier A, Fricker J, Thomasset AL, Apfelbaum M. Fat-free mass estimation by the two-electrode impedance method. Am J Clin Nutr 1990; 52: 581-585.
27. Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN et al. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol 1985; 121: 91-106.
28. Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13: 1476-1484.
29. Canatan H, Bakan I, Akbulut M, Baydas G, Halifeoglu I, Gursu MF. Comparative analysis of plasma leptin levels in both genders of patients with essential hypertension and healthy subjects. Endocr Res 2004; 30: 95-105.
30. Matsubara M, Chiba H, Maruoka S, Katayose S. Elevated serum leptin concentrations in women with components of multiple risk factor clustering syndrome. J Atheroscler Thromb 2000; 7: 231-237.
31. Liuzzi A, Savia G, Tagliaferri M, Lucantoni R, Berselli ME, Petroni ML et al. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord 1999; 23: 1066-1073.
32. El-Gharbawy AH, Kotchen JM, Grim CE, Kaldunski M, Hoffmann RG, Pausova Z et al. Gender-specific correlates of leptin with hypertension-related phenotypes in African Americans. Am J Hypertens 2002; 15: 989-993.
33. Lyoussi B, Ragala MA, Mguil M, Chraibi A, Israili ZH. Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans. Clin Exp Hypertens 2005; 27: 377-394.
34. Hu FB, Chen C, Wang B, Stampfer MJ, Xu X. Leptin concentrations in relation to overall adiposity, fat distribution, and blood pressure in a rural Chinese population. Int J Obes Relat Metab Disord 2001; 25: 121-125.
35. Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 2004; 89: 2665-2671.
36. Della MP, Lupia M, Bandolin V, Guzzon S, Sonino N, Vettor R et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005; 18: 30-35.
37. Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: 103-104.
38. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004; 150: 715-718.
39. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
40. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 2003; 52: 1182-1186.
41. Rajala MW, Scherer PE. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 3765-3773.
42. Kim MS, Lee KU. Role of hypothalamic 5′-AMP-activated protein kinase in the regulation of food intake and energy homeostasis. J Mol Med 2005; 83: 514-520.
43. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
44. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
45. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145: 367-383.
46. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99: 16309-16313.
47. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108-1116.
48. Fagerberg B, Hulten LM, Hulthe J. Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1460-1463.
49. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
50. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
51. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005; 51: 578-585.
52. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005; 29: 1315-1320.
53. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006; 91: 2755-2760.
54. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 150-156.
55. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856.
56. Lavoie HB, Taylor AE, Sharpless JL, Anderson EJ, Strauss CC, Hall JE. Effects of short-term hormone replacement on serum leptin levels in postmenopausal women. Clin Endocrinol (Oxf) 1999; 51: 415-422.
57. Elbers JMH, de Roo GW, Popp-Snijders C, Nicolaas-Merkus A, Westerveen E, Joenje BW et al. Effects of administration of 17beta-oestradiol on serum leptin levels in healthy postmenopausal women. Clin Endocrinol 1999; 51: 449-454.
58. Haffner SM, Mykkanen L, Stern MP. Leptin concentrations in women in the San Antonio Heart Study: effect of menopausal status and postmenopausal hormone replacement therapy. Am J Epidemiol 1997; 146: 581-585.
59. Im JA, Lee JW, Lee HR, Lee DC. Plasma adiponectin levels in postmenopausal women with or without long-term hormone therapy. Maturitas 2006; 54: 65-71.
60. Expert panel on the identification, evaluation, and treatment of overweight and obesity in adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-1867.
61. Wildman RP, Schott LL, Brockwell S, Kuller LH, Sutton-Tyrrell K. A dietary and exercise intervention slows menopause-associated progression of subclinical atherosclerosis as measured by intima-media thickness of the carotid arteries. J Am Coll Cardiol 2004; 44: 579-585.
62. Wildman RP, Colvin AB, Powell LH, Matthews KA, Everson-Rose SA, Hollenberg SM et al. Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN). Menopause 2007 (in press).